Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Items 201–291 of 291
Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas
Nathan, C. O., Carter, P., Liu, L., Li, B. D. �., Abreo, F. W., Tudor, A., Zimmer, S. G., & Benedetti, A. D. (1997) · Oncogene · doi:10.1038/sj.onc.1201272 · Cited by 122
Robert, F., Kapp, L. D., Khan, S. N., Acker, M. G., Kolitz, S., Kazemi, S., Kaufman, R. J., Merrick, W. C., Koromilas, A. E., Lorsch, J. R., et al. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-06-0478 · Cited by 121
Self-citationChemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target
Chen, T., Ozel, D., Qiao, Y., Harbinski, F., Chen, L., Denoyelle, S., He, X., Zvereva, N., Supko, J. G., Chorev, M., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.613 · Cited by 120
Comtesse, N., Keller, A., Diesinger, I., Bauer, C., Kayser, K., Huwer, H., Lenhof, H., & Meese, E. U. (2007) · International Journal of Cancer · doi:10.1002/ijc.22585 · Cited by 118
Yanagiya, A., Svitkin, Y. V., Shibata, S., Mikami, S., Imataka, H., & Sonenberg, N. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01187-08 · Cited by 116
Self-citationRinker‐Schaeffer, C. W., Graff, J. R., De Benedetti, A., Zimmer, S. G., & Rhoads, R. E. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550525 · Cited by 114
LARP1 specifically recognizes the 3′ terminus of poly(A) mRNA
Aoki, K., Adachi, S., Homoto, M., Kusano, H., Koike, K., & Natsume, T. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.035 · Cited by 113
Coleman, L. J., Peter, M. B., Teall, T. J., Brannan, R. A., Hanby, A. M., Honarpisheh, H., Shaaban, A. M., Smith, L., Speirs, V, Verghese, E. T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605044 · Cited by 112
Bunpo, P., Dudley, A., Cundiff, J. K., Cavener, D. R., Wek, R. C., & Anthony, T. G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047910 · Cited by 111
Johnson, L. F., Levis, R., Abelson, H. T., Green, H., & Penman, S. (1976) · The Journal of cell biology · doi:10.1083/jcb.71.3.933 · Cited by 111
Post‐transcriptional regulatory networks in immunity
Ivanov, P., & Anderson, P. (2013) · Immunological Reviews · doi:10.1111/imr.12051 · Cited by 111
The protein kinase PKR: a molecular clock that sequentially activates survival and death programs
Donzé, O., Deng, J., Curran, J. A., SLADEK, R. M., Picard, D., & Sonenberg, N. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600078 · Cited by 110
Self-citationJanes, M. R., Vu, C., Mallya, S., Shieh, M. P., Limon, J. J., Li, L.-S., Jessen, K. A., Martin, M. B., Ren, P., Lilly, M. B., et al. (2013) · Leukemia · doi:10.1038/leu.2012.276 · Cited by 109
Cap‐Dependent Translation Initiation Factor e IF4E: An Emerging Anticancer Drug Target
Jia, Y., Polunovsky, V., Bitterman, P. B., & Wagner, C. R. (2012) · Medicinal Research Reviews · doi:10.1002/med.21260 · Cited by 107
Blocking eIF4E-eIF4G Interaction as a Strategy To Impair Coronavirus Replication
Cencic, R., Desforges, M., Hall, D. R., Kozakov, D., Du, Y., Min, J., Dingledine, R., Fu, H., Vajda, S., Talbot, P. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00078-11 · Cited by 107
Self-citationKuznetsov, G., Xu, Q., Rudolph-Owen, L., TenDyke, K., Liu, J., Towle, M., Zhao, N., Marsh, J., Agoulnik, S., Twine, N., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1026 · Cited by 105
Tumor suppression by small molecule inhibitors of translation initiation
Chen, L., Aktas, B. H., Wang, Y., He, X., Sahoo, R., Zhang, N., Denoyelle, S., Kabha, E., Yang, H., Yefidoff Freedman, R., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.598 · Cited by 104
Translation factors and ribosomal proteins control tumor onset and progression: how?
Loreni, F., Mancino, M., & Biffo, S. (2013) · Oncogene · doi:10.1038/onc.2013.153 · Cited by 103
Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia
Tsumuraya, T., Ishikawa, C., Machijima, Y., Nakachi, S., Senba, M., Tanaka, J., & Mori, N. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.025 · Cited by 101
DeFatta, R. J., Nathan, C. O., & Benedetti, A. D. (2000) · The Laryngoscope · doi:10.1097/00005537-200006000-00007 · Cited by 100
Topisirovic, I., Siddiqui, N., Orolicki, S., Skrabanek, L. A., Tremblay, M., Hoang, T., & Borden, K. L. B. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01532-08 · Cited by 100
Papadopoulos, E., Jenni, S., Kabha, E., Takrouri, K., Yi, T., Salvi, N., Luna, R. E., Gavathiotis, E., Poornachandran, M., Arthanari, H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410250111 · Cited by 99
MAP Kinase-Interacting Kinases—Emerging Targets against Cancer
Diab, S., Kumarasiri, M., Yu, M., Teo, T., Proud, C. G., Milne, R. W., & Wang, S. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.01.011 · Cited by 97
Metformin and Cancer: Mounting Evidence Against an Association
Suissa, S., & Azoulay, L. (2014) · Diabetes Care · doi:10.2337/dc14-0500 · Cited by 93
mRNA Translation and Energy Metabolism in Cancer: The Role of the MAPK and mTORC1 Pathways
Topisirovic, I., & Sonenberg, N. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010785 · Cited by 92
Self-citationTargeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis
Lin, C.-J., Nasr, Z., Premsrirut, P. K., Porco, J. A., Hippo, Y., Lowe, S. W., & Pelletier, J. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.010 · Cited by 90
Self-citationMiloslavski, R., Cohen, E., Avraham, A., Iluz, Y., Hayouka, Z., Kasir, J., Mudhasani, R., Jones, S. N., Cybulski, N., Rüegg, M. A., et al. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju008 · Cited by 87
Li, S., Jia, Y., Jacobson, B., McCauley, J., Kratzke, R., Bitterman, P. B., & Wagner, C. R. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300699d · Cited by 86
Diab, S., Teo, T., Kumarasiri, M., Li, P., Yu, M., Lam, F., Basnet, S. K. C., Sykes, M. J., Albrecht, H., Milne, R. W., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300552 · Cited by 85
Ghosh, B., Benyumov, A. O., Ghosh, P., Jia, Y., Avdulov, S., Dahlberg, P. S., Peterson, M., Smith, K., Polunovsky, V. A., Bitterman, P. B., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb9000475 · Cited by 85
Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors
Liu, T., Nair, S. J., Lescarbeau, A., Belani, J., Peluso, S., Conley, J., Tillotson, B., O’Hearn, P., Smith, S., Slocum, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011542 · Cited by 84
Pancreatic tumours escape from translational control through 4E-BP1 loss
Martineau, Y., Azar, R., Müller, D., Lasfargues, C., Khawand, S. E., Anesia, R., Pelletier, J., Bousquet, C., & Pyronnet, S. (2013) · Oncogene · doi:10.1038/onc.2013.100 · Cited by 82
Self-citationGupta, S. V., Sass, E. J., Davis, M. E., Edwards, R. B., Lozanski, G., Heerema, N. A., Lehman, A., Zhang, X., Jarjoura, D., Byrd, J. C., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9276-7 · Cited by 81
The interaction of eIF4E with 4E‐BP1 is an induced fit to a completely disordered protein
Fletcher, C. M., & Wagner, G. (1998) · Protein Science · doi:10.1002/pro.5560070720 · Cited by 81
Meric‐Bernstam, F., Chen, H., Akçakanat, A., Do, K.-A., Lluch, A. M., Hennessy, B. T., Hortobágyi, G. N., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3343 · Cited by 80
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
Cope, C. L., Gilley, R., Balmanno, K., Sale, M. J., Howarth, K. D., Hampson, M., Smith, P. D., Guichard, S. M., & Cook, S. J. (2013) · Journal of Cell Science · doi:10.1242/jcs.137588 · Cited by 79
Lynch, M., Fitzgerald, C., Johnston, K. A., Wang, S., & Schmidt, E. V. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310872200 · Cited by 73
Ribosomal dysfunction and inherited marrow failure
Ganapathi, K. A., & Shimamura, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07095.x · Cited by 73
Lin, C., Malina, A., & Pelletier, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0813 · Cited by 73
Self-citationKo, S. Y., Guo, H., Barengo, N., & Naora, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2924 · Cited by 72
Toward a Genome-Wide Landscape of Translational Control
Larsson, O. S., Tian, B., & Sonenberg, N. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012302 · Cited by 70
Self-citationTu, L., Liu, Z., He, X., He, Y., Yang, H., Jiang, Q., Xie, S., Xiao, G., Li, X., Yao, K., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-78 · Cited by 69
Ramalingam, S., Gediya, L. K., Kwegyir‐Afful, A. K., Ramamurthy, V. P., Purushottamachar, P., Mbatia, H. W., & Njar, V. C. O. (2014) · Oncotarget · doi:10.18632/oncotarget.1528 · Cited by 68
Translational control of ornithine aminotransferase. Modulation by initiation factor eIF-4E.
Fagan, R. J., Lazaris-Karatzas, A., Sonenberg, N., & Rozen, R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55331-x · Cited by 66
Self-citationModifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A
Cencic, R., Robert, F., Galicia-Vázquez, G., Malina, A., Ravindar, K., Somaiah, R., Pierre, P., Tanaka, J., Deslongchamps, P., & Pelletier, J. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.25 · Cited by 66
Self-citationTargeting Translation Dependence in Cancer
Malina, A., Cencic, R., & Pelletier, J. (2011) · Oncotarget · doi:10.18632/oncotarget.218 · Cited by 66
Self-citationGao, F., Wang, X., Zhu, F., Wang, Q., Zhang, X., Guo, C., Zhou, C., Ma, C., Sun, W., Zhang, Y., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00497.x · Cited by 66
Emerging Therapeutics Targeting mRNA Translation
Malina, A., Mills, J. R., & Pelletier, J. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012377 · Cited by 65
Self-citationLarsson, O., Perlman, D. M., Fan, D., Reilly, C. S., Peterson, M., Dahlgren, C., Liang, Z., Li, S., Polunovsky, V. A., Wahlestedt, C., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl558 · Cited by 64
Tschopp, C., Knauf, U., Brauchle, M. A., Zurini, M. G. M., Ramage, P., Glück, D., New, L., Han, J., & Gram, H. (2000) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.2000.0217 · Cited by 63
Jasiulionis, M. G., Luchessi, A. D., Moreira, A. G., Souza, P. P. C., Suenaga, A. P. M., Correa, M., Costa, C. A. S., Curi, R., & Costa‐Neto, C. M. (2007) · Cell Biochemistry and Function · doi:10.1002/cbf.1351 · Cited by 62
Yi, T., Papadopoulos, E., Hagner, P. R., & Wagner, G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.471466 · Cited by 62
In vitro inhibition of translation initiation by N,N′-diarylureas—potential anti-cancer agents
Denoyelle, S., Chen, T., Chen, L., Wang, Y., Klosi, E., Halperin, J. A., Aktas, B. H., & Chorev, M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.10.126 · Cited by 60
Inhibition of Protein Synthesis in Intact HeLa Cells
Tscherne, J. S., & Pestka, S. (1975) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.8.4.479 · Cited by 58
Astanehe, A., Finkbeiner, M., Krzywinski, M. I., Fotovati, A., Dhillon, J., Berquin, I. M., Mills, G. B., Marra, M. A., & Dunn, S. E. (2012) · Oncogene · doi:10.1038/onc.2011.617 · Cited by 58
Liang, S., Zhou, Y., Chen, Y., Ke, G., Wen, H., & Wu, X. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000152 · Cited by 55
Zindy, P., Bergé, Y., Allal, B., Filleron, T., Pierredon, S., Cammas, A., Beck, S., Mhamdi, L., Fan, L., Favre, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0420 · Cited by 55
Chen, C., Hsieh, F., Cheng, Y., Lee, P., & Chang, K. (2004) · Journal of Surgical Oncology · doi:10.1002/jso.20037 · Cited by 54
Zheng, J., Li, J., Xu, L., Xie, G., Wen, Q., Luo, J., Li, D., Huang, D., & Fan, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089220 · Cited by 53
Low, W., Li, J., Zhu, M., Kommaraju, S. S., Shah-Mittal, J., Hull, K., Liu, J. O., & Romo, D. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.046 · Cited by 50
Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap
Yan, Y., Svitkin, Y. V., Lee, J. M., Bisaillon, M., & Pelletier, J. (2005) · RNA · doi:10.1261/rna.2930805 · Cited by 50
Self-citationDynamic Recognition of the mRNA Cap by Saccharomyces cerevisiae eIF4E
O’Leary, S. E., Petrov, A. N., Chen, J., & Puglisi, J. D. (2013) · Structure · doi:10.1016/j.str.2013.09.016 · Cited by 48
Targeting TOR dependence in cancer
Janes, M. R., & Fruman, D. A. (2010) · Oncotarget · doi:10.18632/oncotarget.110 · Cited by 45
Mnk kinases in cytokine signaling and regulation of cytokine responses
Joshi, S., & Platanias, L. C. (2015) · Biomolecular Concepts · doi:10.1515/bmc-2011-2000 · Cited by 44
Westman, B. J., Beeren, L., Grudzien‐Nogalska, E., Stȩpiński, J., Worch, R., Zuberek, J., Jemielity, J., Stolarski, R., Darżynkiewicz, E., Rhoads, R. E., et al. (2005) · RNA · doi:10.1261/rna.2132505 · Cited by 44
Żochowska, M., Piguet, A.-C., Jemielity, J., Kowalska, J., Szołajska, E., Dufour, J., & Chroboczek, J. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.07.009 · Cited by 44
Walsh, D., & Mohr, I. (2014) · Genes & Development · doi:10.1101/gad.236752.113 · Cited by 43
Haydon, M. S., Googe, J. D., Sorrells, D. S., Ghali, G. E., & Li, B. D. �. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12<2803::aid-cncr20>3.0.co;2-5 · Cited by 43
Hamamura, K., Minami, K., Tanjung, N., Wan, Q., Koizumi, M., Matsuura∥, N., NA, S., & Yokota, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2366 · Cited by 42
Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
Mallya, S., Fitch, B. A., Lee, J. S., So, L., Janes, M. R., & Fruman, D. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088865 · Cited by 41
Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.
Wang, X., Wei, Z., Gao, F., Zhang, X., Zhou, C., Zhu, F., Wang, Q., Gao, Q., Ma, C., Sun, W., et al. (2008) · PubMed · Cited by 41
Willimott, S., Beck, D., Ahearne, M. J., Adams, V., & Wagner, S. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2185 · Cited by 40
Hariri, F., Argüello, M., Volpon, L., Čuljković, B., Nielsen, T. H., Hiscott, J. B., Mann, K. K., & Borden, K. L. B. (2013) · Leukemia · doi:10.1038/leu.2013.73 · Cited by 38
Mnk kinases in cytokine signaling and regulation of cytokine responses
Joshi, S., & Platanias, L. C. (2012) · Biomolecular Concepts · doi:10.1515/bmc-2011-1057 · Cited by 37
Rapamycin Resistance: mTORC1 Substrates Hold Some of the Answers
Yoon, S.-O., & Roux, P. P. (2013) · Current Biology · doi:10.1016/j.cub.2013.08.030 · Cited by 36
Koromilas, A. E., & Mounir, Z. (2013) · Future Oncology · doi:10.2217/fon.13.49 · Cited by 36
Li, X., Xin, S., Yang, D., Li, X., He, Z., Che, X., Wang, J., Chen, F., Wang, X., & Song, X. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1121-y · Cited by 34
Buaboonnam, J., Cao, X., Pauley, J. L., Pui, C., Ribeiro, R. C., Rubnitz, J. E., & Inaba, H. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24470 · Cited by 33
Xu, J., Chen, A., Joy, J. K., Xavier, V. J., Ong, E. H., Hill, J., & Chai, C. L. L. (2013) · ChemMedChem · doi:10.1002/cmdc.201300231 · Cited by 30
Satheesha, S., Cookson, V. J., Coleman, L., Ingram, N., Madhok, B., Hanby, A. M., Suleman, C. A. B., Sabine, V. S., Macaskill, E. J., Bartlett, J. M. S., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-19 · Cited by 30
Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer
Sale, M. J., & Cook, S. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140129 · Cited by 28
Figlin, R. A. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1173 · Cited by 25
y Cajal, S. R., Mattos‐Arruda, L. D., Sonenberg, N., Cortés, J., & Peg, V. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1203-9 · Cited by 22
Self-citationSimplified Silvestrol Analogues with Potent Cytotoxic Activity
Hawkins, B. C., Lindqvist, L., Nhu, D., Sharp, P. P., Segal, D., Powell, A. K., Campbell, M., Ryan, E., Chambers, J. M., White, J. M., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201400024 · Cited by 21
Hall, M. N. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130092 · Cited by 20
mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
Alain, T., Sonenberg, N., & Topisirović, I. (2012) · Oncotarget · doi:10.18632/oncotarget.799 · Cited by 19
Self-citationKhanna‐Gupta, A., Abayasekara, N., Levine, M. S., Sun, H., Virgilio, M., Nia, N., Halene, S., Sportoletti, P., Jeong, J., Pandolfi, P. P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.373274 · Cited by 18
Translation of viral mRNAs that do not require eIF4E is blocked by the inhibitor 4EGI-1
Redondo, N., García-Moreno, M., Sanz, M. Á., & Carrasco, L. (2013) · Virology · doi:10.1016/j.virol.2013.06.008 · Cited by 10
Chironna, M., Calabrò, M. L., Quarto, M., Germinario, C. A., Fiore, J. R., Favero, A., Potenza, D., Chieco‐Bianchi, L., & Barbuti, S. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960315)65:6<778::aid-ijc12>3.0.co;2-0 · Cited by 7
Protein synthesis and translational control: at eye level with the ribosome
Leppek, K., Schott, J., & Stoecklin, G. (2011) · EMBO Reports · doi:10.1038/embor.2011.224 · Cited by 7
L-Asparaginase Therapy for Leukemia and Other Malignant Neoplasms: Remission in Human Leukemia
Hill, J. M. (1967) · JAMA · doi:10.1001/jama.1967.03130220070012 · Cited by 1
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
RNA sequencing: the teenage years
Stark, R., Grzelak, M., & Hadfield, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0150-2 · Cited by 1,915
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
Self-citationRNA-Binding Proteins in Cancer: Old Players and New Actors
Pereira, B., Billaud, M., & Almeida, R. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.05.003 · Cited by 773
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
“recognition by eukaryotic initiation factor 4F (eIF4F) and the assembly of the preinitiation complex (PIC), which consists of the ternary complex, the 40S ribosomal subunit, eIF1, eIF1A, eIF3 and eIF5.(21) eIF4F consists of eIF4A, eIF4E and eIF4G, which facilitates PIC recruitment by eIF4E–cap and eIF4G–eIF3 interacti…”
Background
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.